{"id":47599,"date":"2024-04-03T06:11:33","date_gmt":"2024-04-03T06:11:33","guid":{"rendered":"https:\/?p=47599"},"modified":"2024-04-03T06:11:33","modified_gmt":"2024-04-03T06:11:33","slug":"celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/","title":{"rendered":"Celcuity: Can This Biotech Be the Next Blockbuster on Wall Street?"},"content":{"rendered":"<p><span style=\"font-weight: 400;\"><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/CELC\">Celcuity LLC (CELC: NSD)<\/a>, a clinical-stage biotech company, is setting its sights on becoming a major player in the fight against cancer. Here is our comprehensive analysis related to Celcuity stock.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Is Celcuity&#8217;s Charm Legitimate?<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Celcuity focuses on developing targeted therapies for cancer treatment. It is making strides with its lead candidate Gedatolisib presently in Phase 3 trials. Successful FDA approval could possibly usher it into &#8220;blockbuster drug&#8221; status. The company has demonstrated a 6% increase in stock price over the past year and earned notable attention from biotech investors due to its progress and potential success.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Stock Target Advisor\u2019s Analysis on Celcuity:<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Stock Target Advisor offers a counter perspective bearing a Stock Rating of Strong Sell and a Target Price of $28.20. The projected Price Change over 12 months is potentially 43.58%.\u00a0<\/span><\/p>\n<p><!-- STA Widget BEGIN --><\/p>\n<div>\n<div class=\"sta-analyst-rating-widget-display\">\n<p><a style=\"text-decoration: none; color: #4b6db5 !important;\" href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/CELC\" target=\"_blank\" rel=\"noopener\">CELC Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n<p><script class=\"analyst-rating\" type=\"text\/javascript\" src=\"https:\/\/www.stocktargetadvisor.com\/assets\/js\/analyst_rating_widget.js\" data-symbol=\"CELC\" data-theme=\"wt_bg_trans\" data-uid=\"1097766494660cf001357e6660cf001357e7\" data-width=\"700\" >\n\t\t<\/script><\/p>\n<\/div>\n<p><span style=\"font-weight: 400;\">Currently, 4 analysts cover CELC, giving an Average Analyst Rating of Strong Buy with a target price of $27.67. However, the analyst target price spectrum is wide, ranging from a low of $23 to a high of $40.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Investors should note that while Celcuity has demonstrated superior risk-adjusted returns, these come with negative cash flow and high volatility. Overpricing compared to book value and high leverage are other flags indicating potential risk.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Conclusion:\u00a0<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Celcuity offers an intriguing proposition for investors. Grounded progress in its clinical trials, coupled with potential blockbuster drug status presents a significant upside. These insights will aid every potential investor in making an informed decision about Celcuity LLC.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Celcuity LLC (CELC: NSD), a clinical-stage biotech company, is setting its sights on becoming a major player in the fight against cancer. Here is our&#8230;<\/p>\n","protected":false},"author":17,"featured_media":47601,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-47599","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Celcuity: Can This Biotech Be the Next Blockbuster on Wall Street?<\/title>\n<meta name=\"description\" content=\"Celcuity stock surges with cancer drug Gedatolisib in Phase 3 trials. Could this be the next biotech blockbuster?\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celcuity: Can This Biotech Be the Next Blockbuster on Wall Street?\" \/>\n<meta property=\"og:description\" content=\"Celcuity stock surges with cancer drug Gedatolisib in Phase 3 trials. Could this be the next biotech blockbuster?\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-03T06:11:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/04\/STAs-Blog-Images-4.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Muzzammil Ahmad\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/Muzzammil625\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Muzzammil Ahmad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/\"},\"author\":{\"name\":\"Muzzammil Ahmad\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\"},\"headline\":\"Celcuity: Can This Biotech Be the Next Blockbuster on Wall Street?\",\"datePublished\":\"2024-04-03T06:11:33+00:00\",\"dateModified\":\"2024-04-03T06:11:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/\"},\"wordCount\":256,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/\",\"name\":\"Celcuity: Can This Biotech Be the Next Blockbuster on Wall Street?\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2024-04-03T06:11:33+00:00\",\"dateModified\":\"2024-04-03T06:11:33+00:00\",\"description\":\"Celcuity stock surges with cancer drug Gedatolisib in Phase 3 trials. Could this be the next biotech blockbuster?\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celcuity: Can This Biotech Be the Next Blockbuster on Wall Street?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\",\"name\":\"Muzzammil Ahmad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"caption\":\"Muzzammil Ahmad\"},\"description\":\"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/\",\"https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625\"],\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Celcuity: Can This Biotech Be the Next Blockbuster on Wall Street?","description":"Celcuity stock surges with cancer drug Gedatolisib in Phase 3 trials. Could this be the next biotech blockbuster?","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/","og_locale":"en_US","og_type":"article","og_title":"Celcuity: Can This Biotech Be the Next Blockbuster on Wall Street?","og_description":"Celcuity stock surges with cancer drug Gedatolisib in Phase 3 trials. Could this be the next biotech blockbuster?","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2024-04-03T06:11:33+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/04\/STAs-Blog-Images-4.jpg","type":"image\/jpeg"}],"author":"Muzzammil Ahmad","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/Muzzammil625","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Muzzammil Ahmad","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/"},"author":{"name":"Muzzammil Ahmad","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8"},"headline":"Celcuity: Can This Biotech Be the Next Blockbuster on Wall Street?","datePublished":"2024-04-03T06:11:33+00:00","dateModified":"2024-04-03T06:11:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/"},"wordCount":256,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/","name":"Celcuity: Can This Biotech Be the Next Blockbuster on Wall Street?","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2024-04-03T06:11:33+00:00","dateModified":"2024-04-03T06:11:33+00:00","description":"Celcuity stock surges with cancer drug Gedatolisib in Phase 3 trials. Could this be the next biotech blockbuster?","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/celcuity-can-this-biotech-be-the-next-blockbuster-on-wall-street\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Celcuity: Can This Biotech Be the Next Blockbuster on Wall Street?"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8","name":"Muzzammil Ahmad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","caption":"Muzzammil Ahmad"},"description":"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.","sameAs":["https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/","https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625"],"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/47599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=47599"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/47599\/revisions"}],"predecessor-version":[{"id":47602,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/47599\/revisions\/47602"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/47601"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=47599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=47599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=47599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}